MK-0773
Status
No approved product. No FDA-approved labeling exists. Development was discontinued, and no FDA approval was found in Drugs@FDA (checked 25 October 2026). Other countries were not verified for this entry.
What it is
A SARM studied in older women for muscle function then discontinued.
What published research measured
A steroidal selective androgen receptor modulator developed by Merck, and unusual in this category for having reached a substantial human trial. A phase 2 study in older women with sarcopenia reported modest increases in lean body mass, but the improvements in physical function that would have justified the drug did not follow convincingly, and elevations in liver enzymes and reductions in HDL cholesterol were observed. Development was discontinued. That trial is the compound's main human dataset, and it is a discontinuation rather than a success — the honest summary is that a well-resourced sponsor tested it properly and stopped. Prohibited at all times in sport under WADA class S1.2.
Source
Papanicolaou et al. 2013, Journal of Nutrition, Health and Aging — phase 2 trial in sarcopenic older women
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.